Previous 10 | Next 10 |
home / stock / nvo / nvo articles
Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.41% on an annualized basis producing an average annual return of 19...
Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling p...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Apple Inc. (NASDAQ:AAPL) is a “buy here.” Apple's iPhone s...
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous...
Pharmaceutical titan, Novo Nordisk A/S (NYSE:NVO), has had a significant impact on Denmark’s employment landscape, surpassing initial project...
A team of Chinese scientists has successfully cured a patient’s diabetes using cell therapy, marking a global first. What Happened: The patie...
Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug being used ...
Novo Nordisk A/S’s (NYSE:NVO) shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic fo...
News, Short Squeeze, Breakout and More Instantly...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...
2024-07-05 05:45:00 ET With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for other treatments, it's natural for investors to assume that Nov...